More news about Sophia Genetics

SOPHiA GENETICS opens U.S. headquarters in Boston

24.09.2018 16:47

Related tags

Boston

SOPHiA GENETICS has opened operations in Boston to meet the burgeoning demand across the United States. The company has currently 20 people working in the U.S. and it will be expanding to 50 within a year’s time.

In the United States, SOPHiA GENETICS is already supporting more than 100 university hospitals and is rapidly expanding across the region. Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, commented: “We are experiencing a wide and fast adoption of our technology in North America and are very happy to open our U.S. headquarters in Boston and strengthen our team to support customers’ needs. We currently have 20 people working in the U.S. and we will be expanding to 50 within a year’s time.” 

Lars Steinmetz, co-founder of SOPHiA GENETICS and professor at Stanford University added: “When we created SOPHiA GENETICS, we never expected to have such an impact worldwide. Thanks to the expertise and quality delivered by SOPHiA’s dedicated team of experts and its standardized technology SOPHiA, the company has earned the trust of the global genomics community, which is so important to truly accelerate the democratization of Data-Driven Medicine.”

SOPHiA AI (SOPHiA) is the most widely used technology for genomic analysis, adopted by hundreds of university hospitals worldwide. SOPHiA has already analyzed over 250,000 genomic profiles – currently one every five minutes! Utilized in the context of hereditary disorders and cancer, SOPHiA enables clinicians to accurately detect and characterize genomic alterations. Through the company’s platform, experts can unite across borders and use their shared knowledge to efficiently deliver faster outcomes. The company has already offices in London and France.


(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

18.01.2019
Editorial

Good times for pioneers

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS